Vortosiran for VTE Prevention

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 150 participants.

Also called NCT07850453

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07850453
  • EudraCT 2026-525479-15
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Bulgaria, France, Poland, Romania (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07850453. Randomized; quadruple masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2027-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Vortosiran for VTE Prevention
Condition
Venous Thromboembolism (VTE)
Condition
Cancer
Condition
Pulmonary Embolism (Diagnosis)
Intervention (Drug)
Vortosiran
Intervention (Drug)
Placebo
Lead sponsor
Ribocure Pharmaceuticals AB (class: industry)
Collaborator
Fortrea (class: industry)

Record details

Record id
cardio:ct-nct07850453
Content hash
f7e4eed78443aace7d272f14687a53cd6db039b9c3ac5cc4802047ea8a951389